Jump to main content
Jump to site search

Issue 2, 2021
Previous Article Next Article

Single nanoparticle analysis for homogeneous immunoassay of CA19-9 for serological evaluation

Author affiliations

Abstract

Pancreatic cancer is a malignant tumour with high mortality. Surgery after diagnosis at the early stage is the most effective treatment. As the most effective biomarker of pancreatic cancer, CA19-9 has important clinical significance for both early diagnosis and surgical prediction. Herein, a single nanoparticle homogeneous immunoassay based on Au nanoparticle tagging was proposed for CA19-9 determination, with a dynamic range from 6.25 to 400 U mL−1 in intensity mode and 6.25 to 100 U mL−1 in frequency mode. The limits of detection were 0.72 U mL−1 (intensity mode) and 0.84 U mL−1 (frequency mode). Accurate results were obtained without any washing and separation procedure, and the matrix effect was avoided by monitoring both the intensity and frequency signal obtained from single nanoparticles. The method was successfully applied to the serological evaluation of patients. The results were well correlated with those measured by conventional clinical methods, demonstrating a promising foreground in the preoperative assessment of resectability and evaluation of disease recurrence.

Graphical abstract: Single nanoparticle analysis for homogeneous immunoassay of CA19-9 for serological evaluation

Back to tab navigation

Supplementary files

Article information


Submitted
07 Nov 2020
Accepted
07 Jan 2021
First published
08 Jan 2021

J. Anal. At. Spectrom., 2021,36, 279-284
Article type
Paper

Single nanoparticle analysis for homogeneous immunoassay of CA19-9 for serological evaluation

M. Jiang, Z. Huang, X. Zhao, R. Liu and Y. Lv, J. Anal. At. Spectrom., 2021, 36, 279
DOI: 10.1039/D0JA00464B

Social activity

Search articles by author

Spotlight

Advertisements